Ethyreal Bio
PrivateLast Round
Series B
Jun 10, 2026
Total Funding Raised
$101M
Momentum
Top 10%
of companies Caplight tracks
Company Overview
Ethyreal Bio operates in Healthcare & Life Sciences and is based in Cambridge, Massachusetts. Its latest recorded funding round was a Series B round in June 2026.
Ethyreal Bio is a biotechnology company developing ETHY-001, a monoclonal antibody antagonist of the thyroid stimulating hormone receptor (TSHR) for the treatment of Graves' disease and thyroid eye disease.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Precision Medicine, Clinical Trials
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Ethyreal Bio Comparables
Compare Ethyreal Bio with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Yarrow Bioscience, Inc. | 90% | |
| Viridian Therapeutics | 76% | |
| Immunovant | 76% |
For institutional investors. Book with your work email.
Ethyreal Bio Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series B | Jun 10, 2026 | ||||
| Series A | Jun 1, 2024 |
For institutional investors. Book with your work email.
Ethyreal Bio Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Avoro Capital | Series B |
| Atlas Venture | Series B, Series A |
| Medicxi | Series B, Series A |
Market signals
Structured signals derived from secondary market and firmographic data.
- Jun 10, 2026
$60M round led by Avoro Capital.
- Jun 1, 2024
$41M round led by Atlas Venture and Medicxi.
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- is_developingOct 19, 2026
Ethyreal Bio advances development of ETHY-001 for TED and GD and initiates the first patient cohorts after Phase 1 proof-of-mechanism results in Massachusetts on Oct 19th '26.
For institutional investors. Book with your work email.
Ethyreal Bio Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Ethyreal Bio's valuation, stock price, and market status.
Is Ethyreal Bio a public or private company?
Ethyreal Bio is a private company.
What is the current stock price of Ethyreal Bio?
Ethyreal Bio is a private company, so its shares have no public market price. Caplight tracks Ethyreal Bio's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Ethyreal Bio worth (valuation)?
Valuation information for Ethyreal Bio is not publicly available.
Can I buy Ethyreal Bio stock?
Ethyreal Bio shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Ethyreal Bio's last funding round?
Ethyreal Bio's most recent funding round was Series B on June 10, 2026.
Who are the main investors in Ethyreal Bio?
Key investors in Ethyreal Bio include Avoro Capital, Atlas Venture, Medicxi.
Will Ethyreal Bio IPO soon?
No public IPO plans have been announced for Ethyreal Bio.
How can I track Ethyreal Bio secondary market activity?
Caplight tracks bids, offers, and trades in Ethyreal Bio's shares on secondary markets.